Acquisition by Roger Jeffs of 5681 shares of Axsome Therapeutics subject to Rule 16b-3

AXSM Stock  USD 89.74  0.93  1.03%   
About 58% of Axsome Therapeutics' investor base is looking to short. The analysis of overall sentiment of trading Axsome Therapeutics stock suggests that many investors are alarmed at this time. Axsome Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in Axsome Therapeutics. Many technical investors use Axsome Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
  
Filed transaction by Axsome Therapeutics Inc director. Grant, award or other acquisition pursuant to Rule 16b-3(d)

Read at macroaxis.com
Axsome insider trading alert for grant of stock option right to buy by Roger Jeffs, the corporate stakeholder, on 6th of June 2023. This event was filed by Axsome Therapeutics Inc with SEC on 2023-06-06. Statement of changes in beneficial ownership - SEC Form 4

Cash Flow Correlation

Axsome Therapeutics' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Axsome Therapeutics' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.
Click cells to compare fundamentals

Axsome Therapeutics Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Axsome Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Axsome Therapeutics Fundamental Analysis

We analyze Axsome Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Axsome Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Axsome Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Price To Book

Price To Book Comparative Analysis

Axsome Therapeutics is currently under evaluation in price to book category among its peers. Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.

Axsome Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Axsome Therapeutics stock to make a market-neutral strategy. Peer analysis of Axsome Therapeutics could also be used in its relative valuation, which is a method of valuing Axsome Therapeutics by comparing valuation metrics with similar companies.

Peers

Axsome Therapeutics Related Equities

MCRBSeres Therapeutics   7.08   
0%
63.0%
MDGLMadrigal Pharmaceuticals   0.22   
0%
1.0%
TGTXTG Therapeutics   0.48   
4.0%
0%
SRPTSarepta Therapeutics   0.65   
5.0%
0%
INCYIncyte   0.73   
6.0%
0%
ACADACADIA Pharmaceuticals   1.06   
9.0%
0%
AKROAkero Therapeutics   1.08   
9.0%
0%
DAWNDay One   1.42   
12.0%
0%
HEPAHepion Pharmaceuticals   5.54   
49.0%
0%
AMLXAmylyx Pharmaceuticals   7.48   
67.0%
0%
BPMCBlueprint Medicines   7.83   
70.0%
0%
PDSBPDS Biotechnology   10.71   
95.0%
0%
TERNTerns Pharmaceuticals   11.03   
98.0%
0%
VKTXViking Therapeutics   11.16   
100.0%
0%
When determining whether Axsome Therapeutics is a strong investment it is important to analyze Axsome Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Axsome Therapeutics' future performance. For an informed investment choice regarding Axsome Stock, refer to the following important reports:
Check out Axsome Therapeutics Hype Analysis, Axsome Therapeutics Correlation and Axsome Therapeutics Performance.
To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.
You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Axsome Therapeutics. If investors know Axsome will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Axsome Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(6.58)
Revenue Per Share
7.108
Quarterly Revenue Growth
0.813
Return On Assets
(0.26)
Return On Equity
(1.72)
The market value of Axsome Therapeutics is measured differently than its book value, which is the value of Axsome that is recorded on the company's balance sheet. Investors also form their own opinion of Axsome Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Axsome Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Axsome Therapeutics' market value can be influenced by many factors that don't directly affect Axsome Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Axsome Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Axsome Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Axsome Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.